1 / 39

IM ischémique

IM ischémique. Tout ce que vous avez toujours voulu savoir sur l’IM ischémique!! Cas clinique mis à disposition par Claire BOULETI. Case Study. 69-year old man Chronic renal failure: creatinine 170 µmol/l

lorna
Télécharger la présentation

IM ischémique

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IM ischémique Tout ce que vous avez toujours voulu savoir sur l’IM ischémique!! Cas clinique mis à disposition par Claire BOULETI

  2. Case Study • 69-year old man • Chronic renal failure: creatinine 170 µmol/l • CV risk factors: smoking 46PY (cessation), hypertension, dyslipidemia, diabetes mellitus

  3. Medical history • 1997 acute pulmonary oedema revealing coronary artery disease with asymptomatic RCA occlusion. • No symptom until December 2003 : • 2nd severe pulmonary oedema without triggering factor. LVEF 40%. Ischaemic MR 2/4. Coronary arteriography: not modified. Favourable evolution • Dyspnea NYHA class II-III without hospitalisation until July 2011 • 3rd pulmonary oedema in July 2011, with fast improvement under medical treatment

  4. Coronary angiography

  5. TTE

  6. TTE: Akinesis in the basal inferior segment, LVEF 30% LVEDD 65mm LVESD 54mm, ERO 60 mm2, RV 66ml vena contracta 8 mm • No left ventricular viability • ECG: Q wave in inferior leads. LBBB (QRS =140ms) • NYHA class III dyspnea refractory to medical treatment (B-, ACE-Inhibitors, diuretics) management of this patient?

  7. TTE: Akinesis in the basal inferior segment, LVEF 30% LVEDD 65mm LVESD 54mm, ERO 60 mm2, RV 66ml vena contracta 8 mm • No left ventricular viability • ECG: Q wave in inferior leads. LBBB (QRS =140ms) • NYHA class III dyspnea refractory to medical treatment (B-, ACE-Inhibitors, diuretics) management of this patient?

  8. ESCGuidelines CRT-P/-D to reduce morbidity and mortality

  9. Medical history • No clinical improvement • 4th pulmonary oedema in October without triggering factor • TTE : no major changes LVEF 25% Akinesis of the basal inferior segment, LVEDD 65mm LVESD 54mm, ERO 60 mm2, RV 66ml vena contracta 8 mm, sPAP 50 mmHg • TEE : same findings

  10. Evaluation of functional MR: Mechanism • Local remodelling ± wall motion abnormalities • Displacement of papillary muscles • Traction on mitral leaflets (tethering) • Tenting • Restriction of anterior leaflet opening • Incomplete mitral leaflet closure (Levine et al. Curr Cardiol Rep 2002;4:125-9)

  11. Evaluation of functional MR: Mechanism • Restriction in the leaflet motion (Carpentier type 3) • Incomplete leaflet closure in systole • is the consequence of changes in geometry • and/or motion of the left ventricle • Normal structure of leaflets and subvalvular apparatus • Imbalance between tethering and closure force

  12. Evaluation of functional MR: Mechanism • Tenting • The volume of regurgitation is related to the importance of tenting and not to LVEF Tenting area (Yiu et al. Circulation 2000;102:1400-6)

  13. Evaluation of functional MR: Quantification (ESC Guidelines)

  14. Back to Mr G • 69-year old male, chronic renal failure • LVEF 25% • Severe functional MR, with symptoms refractory to maximal medical treatment and resynchronisation. • No viability= no possible revascularisation Do we have to correct MR?

  15. Rationale for the Correction of Ischaemic / Functional MR Medical treatment Surgery: MVR/valve repair Mitraclip Options:

  16. The Role of Medical Therapy • Treatments which reduce the degree of • ischaemic MR= treatment of systolic heart failure • ACE inhibitors, AT1 receptors blockers • Beta-blockers • Biventricular pacing • But clinical relevance/pronostic impact on MR remains unclear

  17. Surgery for Functional MR • Prosthetic valve replacement • Preservation of subvalvular apparatus • Valve repair • Undersized annuloplasty • Restores coaptation but does not correct tethering • Limitations of intra-operative TEE • Risk of residual MR > organic MR • + CABG

  18. Surgery for Ischaemic MROperative Mortality

  19. Ischaemic and Non-Ischaemic MRConfounding Factors 535 patients operated on for mitral valve repair (1993-2002) (Glower et al. J Thorac Cardiovasc Surg 2005;129:860-8)

  20. Surgery of Ischaemic MRCABG With or Without Valve Repair • 2 groups, ischaemic MR  3/4 : - 54 had isolated CABG - 54 had CABG + valve repair • No significant difference in survival and NYHA class III-IV • Recurrence of MR after valve repair (Mihajlevic et al. J Am Coll Cardiol 2007;49:2191-201)

  21. Ischaemic MRViability and prognosis • 54 patients with severe ischaemic MR, mean LVEF 27% • Viability on PET scan • Viability and survival following coronary bypass and MV Replacement • (Pu et al. Am J Cardiol 2003;92:862-4)

  22. Surgery for Functional MR vs. Medical Therapy 682 patients with functional MR and severe LV dysfunction 126 had valve repair, 556 were treated medically Mitral annuloplasty was not a predictor of late cardiac events (death, ventricular assistance, or transplantation) (Wu et al. J Am Coll Cardiol 2005;45:381-7)

  23. Impact of Surgery on LV Remodeling • 87 patients operated for ischaemic MR (2000-2004) • 86% MR grade 3/4, LVEF 32 ± 10% • Valve repair (downsized ring) + 86% CABG • 30-day mortality 8.0% • 60% of pts had reverse LV remodeling (10% decrease in LV EDD) at 18 months FU • Thresholds predicting reverse LV remodeling • EDD < 65 mm • ESD < 51 mm (Braun et al. Eur J Cardiothorac Surg 2005;27:847-53)

  24. Reverse remodeling after surgeryUnsolved questions • Role of coronary revascularisation? • Recovery of viable myocardium • Role of MR correction? • Removal of volume overload • Experimental studies suggest that isolated MR correction does not significantly impact LV remodeling. (Guy et al. J Am Coll Cardiol 2004;43:377-83) (Enomoto et al. J Thorac Cardiovasc Surg 2005;129:504-11)

  25. Benefits of Surgical Correction of Ischaemic MR • Decrease of MR • but risk of late recurrence after repair • (Gelsomino et al. Eur Heart J 2008;29:231-40) • Left ventricular reverse remodeling • in 60% of patients, predicted by LV dilatation • (Braun et al. Eur J Cardiothorac Surg 2005;27:847-53) • Improvement of symptoms • controversial findings • No proven benefit on survival • (Wu et al. J Am Coll Cardiol 2005;45:381-7)

  26. Indications for Surgery in Ischaemic MR (ESC Guidelines) • surgery can be considered only in selected patients with severe symptoms despite optimal medical therapy

  27. What about the MitraClip System ?

  28. Percutaneous Valve Repair Using the MitraClip System (* EuroPCR 2009 † ESC 2009)

  29. Percutaneous Valve Repair Using the MitraClip System Grade 1+/ 2+ Franzen et al. At 3 months 87% MR reduction Symptoms 86 % of patients in NYHA class I-II Mean LVEF 23%  28% (ESC 2009) Everest HRR 34 patients with functional MR 83% symptom improvement 74% NYHA I-II at 12 months (EuroPCR 2009) Grade 3+/ 4+ 18% 21% 97% 82% 79% 30 days Baseline 12 months

  30. When to propose a Mitraclip in functional MR? • The device is safe and the technique is feasible. • Efficacious in lowering MR • BUT • No long-term outcome • Only 1 single randomised study (only 27% of functional MR) • AND • Will the patient benefit from this reduction of MR? • Same problem as for surgical treatment of MR… • but at a lower risk

  31. Back to Mr G • He benefited from the MitraClip system • No per-procedural complication • Favourable evolution (out of hospital at D+3)

  32. Post-procedural TTE

  33. Post-procedural TTE

  34. Post-procedural TTE

  35. Conclusion: evaluation of ischaemic MR • Functional MR is a totally different disease than organic MR. • It is frequently associated with severe ischemic heart disease which carries a poor prognosis in itself, and worsens the prognosis. • Quantification of the regurgitation uses specific (lower) thresholds for ischaemic etiologies • Need for a complete evaluation of ischaemic MR • Echocardiography (quantification, mechanism) • Viability and ischemia (radionuclide, stress echo) • LV function • Coronary angiography • Functional tolerance (symptoms)

  36. Conclusion: treatment of ischaemic MR • Operative mortality is higher and long term results are less • satisfying than for organic MR even when using valve repair • Thus, risks/benefits of surgery remain debated and indications are far more restrictive than in organic MR: • if symptoms are refractory to maximal medical therapy • in case of CABG • MitraClip system is of potential interest since the risk of the procedure is low • Need for long-term outcome and randomized studies

More Related